Seval AKPINAR

KORONAVİRÜS HASTALIĞI (COVID-19) İLE İLİŞKİLİ KOAGÜLOPATİ

2019 yılı sonunda Çin’in Wuhan eyaletinde “ağır akut solunum sendromu koronavirus-2 (SARS-CoV-2” olarak adlandırılan, zoonotik kaynaklı yeni bir koronavirus ortaya çıkmıştır. Koronavirüs hastalığı-2019 (COVID-19) olarak adlandırılan infeksiyon Dünya Sağlık Örgütü tarafından global bir pandemi olarak tanımlanmıştır. COVID-19; endotel hasarı, staz ve dolaşan protrombotik faktörlerin artmış düzeylerinin sonucu olan pıhtılaşmanın arttığı bir durumdur. Özellikle yoğun bakım ünitelerinde izlenen hastalarda proflaktik antikoagülan tedaviye rağmen venöz tromboemboli riski artmıştır. Bu derlemede, COVID-19 ilişkili koagülopatinin patofizyolojisine, koagülasyon parametrelerine, değerlendirme ve yaklaşımına ilişkin güncel verileri özetlenmiştir.

COVID-19 Related Coagulopathy

A novel coronavirus of zoonotic origin named “severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)” emerged at the end of 2019, in Wuhan province of China. The infection called COVID-19 was declared by World Health Organization a global pandemic. Coronavirüs disease-2019 (COVID-19) is frequently associated with a hypercoagulable state as a result of endothelial injury, stasis and increased levels of circulating protrombotic factors. Especially patients in intensive care units have an increased risk for venous thromboembolism despite prophylactic anticoagulant treatment. In this review, we summarized current data regarding pathophysiology, coagulation parameters, evaluation and management of COVID-19 associated coagulopathy.

PDF

___

1. https://covid19.who.int (19.07.2020 tarihinde erişilmiştir)
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.
3. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369:m1966.
4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.
5. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020;20:389.
6. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 2000; 84:216.
7. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220:1.
8. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul Vet al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18:1738.
9. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844.
10. Amgalan A, Othman M. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. J Thromb Haemost 2020; 18:1514.
11. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020; 18:1020.
12. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18:1094.
13. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089.
14. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020.
15. Cui S, Chen S, Li X, Liu S, Wang F . Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18: 1421.
16. Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, et al. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open 2020; 3:e2010478.
17. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID- 19 patients. J Thromb Haemost 2020; 18:1743.
18. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9. Epub 2020 Apr 23.
19. Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.J Thromb Thrombolysis. 2020;50(1):211.
20. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.N Engl J Med. 2020; 382(20):e60. Epub 2020 Apr 28.
21. Bellosta R, Luzzani L, Natalini G, Pegorer MA, Attisani L, Cossu LG, et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg. 2020;
22. https://www.hematology.org/covid-19/covid-19-andcoagulopathy (Accessed on July 20, 2020).
23. Akima S, McLintock C, Hunt BJ. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020.
24. https://www.acc.org/latest-incardiology/articles/2020/04/17/14/42/thrombosis-andcoronavirus-disease-2019-covid-19-faqs-for-currentpractice
25. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 Enfeksiyonu Rehberi (Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi). Bilimsel Danışma Kurulu Çalışması, 1 Haziran 2020, Ankara.